[HTML] sciencedirect.com

[HTML][HTML] Real-world effectiveness and safety of sacubitril/valsartan in heart failure: a systematic review

C Proudfoot, R Studer, T Rajput, R Jindal… - International journal of …, 2021 - Elsevier
Background: PARADIGM-HF demonstrated superiority of sacubitril/valsartan (sac/val) over
enalapril in patients with heart failure with reduced ejection fraction (HFrEF). However …
被引用次数：41 相关文章

Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review.

C Proudfoot, R Studer, T Rajput, R Jindal… - … Journal of Cardiology, 2021 - europepmc.org
Background PARADIGM-HF demonstrated superiority of sacubitril/valsartan (sac/val) over
enalapril in patients with heart failure with reduced ejection fraction (HFrEF). However …

Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review

C Proudfoot, R Studer, T Rajput, R Jindal… - INTERNATIONAL …, 2021 - boa.unimib.it
Background: PARADIGM-HF demonstrated superiority of sacubitril/valsartan (sac/val) over
enalapril in patients with heart failure with reduced ejection fraction (HFrEF). However …

Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review

C Proudfoot, R Studer, T Rajput… - International …, 2021 - internationaljournalofcardiology.com
Background: PARADIGM-HF demonstrated superiority of sacubitril/valsartan (sac/val) over
enalapril in patients with heart failure with reduced ejection fraction (HFrEF). However …

Real-world effectiveness and safety of sacubitril/valsartan in heart failure: A systematic review

C Proudfoot, R Studer, T Rajput… - International …, 2021 - pubmed.ncbi.nlm.nih.gov
Background PARADIGM-HF demonstrated superiority of sacubitril/valsartan (sac/val) over
enalapril in patients with heart failure with reduced ejection fraction (HFrEF). However …